Abstract
Type 1 Diabetes is an autoimmune disease most often associated with elevated and uncontrolled blood glucose levels. Therefore patient education and treatment compliance is often focused on disease maintenance through insulin treatment and blood glucose control. Unfortunately insulin therapy alone does not prevent the formation of diabetic complications. In order to find a real cure, the underlying pathology of the disease must be directly addressed. Diabetes is caused by the initial rapid destruction of the insulin producing beta cells of the pancreas by autoreactive T-cells. The autoimmune process is also maintained through dendritic cell auto-antigen presentation and the production of autoantibodies by B cells. Only through some forms of immunotherapy can the immune system be rebalanced to assure the survival of the remaining beta cell population. These techniques include cell ablation, competitive decoy auto-antigens, reduced cell activation, and auto-antigen introduction. Here we will review the current state of these different technologies and their progression through clinical trials for the treatment of type 1 diabetes.
Keywords: Autoimmune Disease, Type 1 Diabetes, Immunotherapy, dendritic cells (DC), antigen-presenting cells (APC), antigen tolerance, Altered peptide ligands (APL), cell depletion, insulin, anti-inflammatory cytokines
Current Pharmaceutical Design
Title: Immunotherapy-Based Strategies for the Treatment of Autoimmune Diabetes: Searching for the Cure
Volume: 17 Issue: 29
Author(s): Brett E. Phillips and Massimo Trucco
Affiliation:
Keywords: Autoimmune Disease, Type 1 Diabetes, Immunotherapy, dendritic cells (DC), antigen-presenting cells (APC), antigen tolerance, Altered peptide ligands (APL), cell depletion, insulin, anti-inflammatory cytokines
Abstract: Type 1 Diabetes is an autoimmune disease most often associated with elevated and uncontrolled blood glucose levels. Therefore patient education and treatment compliance is often focused on disease maintenance through insulin treatment and blood glucose control. Unfortunately insulin therapy alone does not prevent the formation of diabetic complications. In order to find a real cure, the underlying pathology of the disease must be directly addressed. Diabetes is caused by the initial rapid destruction of the insulin producing beta cells of the pancreas by autoreactive T-cells. The autoimmune process is also maintained through dendritic cell auto-antigen presentation and the production of autoantibodies by B cells. Only through some forms of immunotherapy can the immune system be rebalanced to assure the survival of the remaining beta cell population. These techniques include cell ablation, competitive decoy auto-antigens, reduced cell activation, and auto-antigen introduction. Here we will review the current state of these different technologies and their progression through clinical trials for the treatment of type 1 diabetes.
Export Options
About this article
Cite this article as:
E. Phillips Brett and Trucco Massimo, Immunotherapy-Based Strategies for the Treatment of Autoimmune Diabetes: Searching for the Cure, Current Pharmaceutical Design 2011; 17 (29) . https://dx.doi.org/10.2174/138161211798157603
DOI https://dx.doi.org/10.2174/138161211798157603 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell to Cell Spreading of Misfolded Proteins as a Therapeutic Target in Motor Neuron Disease
Current Medicinal Chemistry Preface
Current Medicinal Chemistry Transition of Care for Patients with Diabetes
Current Diabetes Reviews Application of Sulfamic Acid in Organic Synthesis-A Short Review
Current Organic Chemistry Denouement of Chemicals on Amyotrophic Lateral Sclerosis: Is Green Chemistry the Answer
Medicinal Chemistry Evaluation of in-vitro Anti Diabetic Activity of a Siddha Herbo- Mineral Drug
Current Traditional Medicine p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry Proteomic Analysis of Aqueous Humor Proteins Associated with Neovascular Glaucoma Secondary to Proliferative Diabetic Retinopathy
Current Proteomics High-dose Vitamin D Supplementation on Type 1 Diabetes Mellitus Patients: Is there an Improvement in Glycemic Control?
Current Diabetes Reviews Editorial [Hot Topic: Mitochondria as a Pharmacological Target: A Clue for Efficacy and a Reason for Toxicity (Executive Guest Editor: Nadezda Apostolova)]
Current Pharmaceutical Design Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein 1: Recent Developments Concerning Substrates and Inhibitors of a Promising Therapeutic Target
Current Medicinal Chemistry Astrocyte`s RAGE: More Than Just a Question of Mood
Central Nervous System Agents in Medicinal Chemistry Endothelial Dysfunction in Diabetes: The Role of Protein Kinase C
Vascular Disease Prevention (Discontinued) The ASK1-MAP Kinase Signaling in ER Stress and Neurodegenerative Diseases
Current Molecular Medicine Vaccines For Type 1 Diabetes: Prevention or Reversal?
Current Diabetes Reviews Biocomputational Resources Useful For Drug Discovery Against Compartmentalized Targets
Current Pharmaceutical Design Inflammatory Process in Alzheimer’s and Parkinson's Diseases: Central Role of Cytokines
Current Pharmaceutical Design A Simple High Efficiency Intra-Islet Transduction Protocol Using Lentiviral Vectors
Current Gene Therapy Minocycline and Cytoprotection: Shedding New Light on a Shadowy Controversy
Current Drug Delivery Distinct Biomarkers for Early Diagnosis of Diabetic Nephropathy
Current Diabetes Reviews